Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: In-vitro and in-vivo studies

International Journal of Neuropsychopharmacology

Volumn 10, Issue 1, 2007, Pages 31-40

  El Mansari, Mostafa ^a   Wiborg, Ove ^b   Mnie Filali, Ouissame ^a   Benturquia, Nadia ^a   Sánchez, Connie ^c   Haddjeri, Nasser ^a  

^a UNIVERSITÉ LYON 1   (France)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c H LUNDBECK A S   (Denmark)

Author keywords

5 HT1A autoreceptor; Allosteric sites; Dorsal raphe; Escitalopram; Hippocampus; Serotonin; Serotonin transporter

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ANTAGONISM; DRUG INHIBITION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ALLOSTERIC REGULATION; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; CERCOPITHECUS AETHIOPS; CITALOPRAM; COS CELLS; DRUG INTERACTIONS; FLUOXETINE; HIPPOCAMPUS; MALE; MICRODIALYSIS; PAROXETINE; PROTEIN BINDING; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; TRANSFECTION;

EID: 33846303559     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006462     Document Type: Article

References (27)

1. Aghajanian GK (1978). Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. Essays in Neurochemistry and Neuropharmacology 3, 1-32.
2. Benturquia N, Couderc F, Sauvinet V, Orset C, Parrot S, Bayle C, Renaud B, Denoroy L (2005). Analysis of serotonin in brain microdialysates using capillary electrophoresis and native laser-induced fluorescence detection. Electrophoresis 26, 1071-1079.
3. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences 15, 220-226.
4. Blier P, de Montigny C (1999). Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21 (2 Suppl.), 91S-98S.
5. Chen F, Larsen MB, Neubauer HA, Sánchez C, Plenge P, Wiborg O (2005b). Characterization of an allosteric citalopram-binding site at the serotonin transporter. Journal of Neurochemistry 92, 21-28.
6. Chen F, Larsen MB, Sánchez C, Wiborg O (2005a). The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European Neurpsychopharmacology 15, 193-198.
7. Cremers TIF, Westerink BHC, Sánchez C (2004). A pharmacological basis for a sub-classification of SSRIs. R-citalopram interacts differently with SSRI in vivo. European Neuropsychopharmacology 14 (Suppl. 3), S387.
8. Czachura JF, Rasmussen K (2000). Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedeberg's Archives of Pharmacology 362, 266-275.
9. El Mansari M, Sánchez C, Chouvet G, Renaud B, Haddjeri N (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo eletrophysiological study in rat brain. Neuropsychopharmacology 30, 1269-1277.
10. Fish EW, Faccidomo S, Gupta S, Miczek KA (2004). Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. Journal of Pharmacology and Experimental Therapeutics 308, 474-480.
11. Fuller RW (1995). Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Progress in Drug Research 45, 167-204.
12. Haddjeri N, Blier P, de Montigny C (1997). Effects of long-term treatment with the alpha-2 adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedeberg's Archives of Pharmacology 355, 20-29.
13. Haddjeri N, El Mansari M, Mnie-Filali O, Benturquia N, Faure C, Chouvet G, Berod A, Sánchez C (2005). In vivo allosteric modulation of the effects of escitalopram on the rat 5-HT neurotransmission and hippocampal neuroplasticity. European Neuropsychopharmacology 15 (Suppl. 3), S432.
14. Hyttel J, Bogeso KP, Perregaard J, Sánchez C (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. Journal of Neural Transmission (General Section) 88, 157-160.
15. Lepola UM, Wade A, Andersen HF (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. International Clinical Psychopharmacology 19, 149-155.
16. Mnie-Filali O, El Mansari M, Espana A, Sánchez C, Haddjeri N (2005). Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity. Neuroscience Letters. Published online 2005. doi:10.1016/j.neulet.2005. 10.044.
17. Mongeau R, Blier P, de Montigny C (1997). The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Research. Brain Research Reviews 23, 145-195.
18. Mørk A, Kreilgaard M, Sánchez C (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45, 167-173.
19. 3H]paroxetine binding to platelet and neuronal membranes. European Journal of Pharmacology 119, 1-8.
20. 3H] citalopram binding to the 5-HT transporter from brain and platelets. European Journal of Pharmacology 206, 243-250.
21. Sánchez C (2003). R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. European Journal of Pharmacology 464, 155-158.
22. Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174, 163-176.
23. Sánchez C, Gruca P, Bien E, Papp M (2003b). R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacology, Biochemistry and Behavior 75, 903-907.
24. Sánchez C, Gruca P, Papp M (2003a). R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behavioural Pharmacology 14, 465-470.
25. Sánchez C, Kreilgaard M (2004). R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacology, Biochemistry and Behavior 77, 391-398.
26. Stórustovu S, Sánchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004). R-citalopram functionally antagonizes escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. British Journal of Pharmacology 142, 172-180.
27. Wennogle LP, Meyerson LR (1985). Serotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelet membranes. Life Science 36, 1541-1550.